Related Experiment Videos
Future developments and new research in genitourinary cancers. Perspectives
Abstract:
Significant advances in the therapy of genitourinary cancers have occurred, yet the challenge of metastatic disease in many of these tumors remains unsolved. The great success achieved in the treatment of testicular cancer has been in large part due to the development of effective systemic therapy. Effective treatment for metastatic transitional cell carcinoma is just beginning to be described. Advanced renal and prostatic carcinomas remain a major clinical problem with no effective curative therapy. Novel new approaches to systemic therapy developed on sound basic experimental principles are needed. Several potential approaches such as angiogenesis factor, interleukin II, lymphokine activated killer cells, and tumor necrosis factor are discussed.
Insights
Advances in genitourinary cancer therapy show promise, but metastatic disease remains a challenge. New systemic therapies, including angiogenesis factors and immunotherapy, are needed for advanced renal and prostate cancers.
Area of Science:
- Oncology
- Genitourinary Cancer Therapy
- Systemic Therapy
Background:
- Significant progress has been made in treating genitourinary cancers.
- Metastatic disease in many genitourinary tumors remains a significant clinical challenge.
- Testicular cancer treatment has seen success due to effective systemic therapy.
Purpose of the Study:
- To review advances in genitourinary cancer therapy.
- To highlight the unmet need for effective treatments for metastatic disease, particularly in renal and prostatic carcinomas.
- To discuss novel systemic therapy approaches based on basic experimental principles.
Main Methods:
- Review of current literature on genitourinary cancer therapy.
- Discussion of emerging systemic therapy modalities.
- Exploration of potential therapeutic targets and agents.
Main Results:
- Effective systemic therapy has revolutionized testicular cancer treatment.
- Effective treatments for metastatic transitional cell carcinoma are emerging.
- Advanced renal and prostatic carcinomas currently lack effective curative therapies.
Conclusions:
- Novel systemic therapy approaches are crucial for addressing metastatic genitourinary cancers.
- Potential strategies include targeting angiogenesis, and utilizing immunotherapy agents like interleukin II, lymphokine-activated killer cells, and tumor necrosis factor.